1331 related articles for article (PubMed ID: 21624412)
21. Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus Influenzae type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China.
Li RC; Li FX; Li YP; Hou QM; Li CG; Li YN; Chen FS; Hu XZ; Su WB; Zhang SM; Fang HH; Ye Q; Zeng TD; Liu TX; Li XB; Huang YN; Deng ML; Zhang YP; Ortiz E
Vaccine; 2011 Feb; 29(10):1913-20. PubMed ID: 21219984
[TBL] [Abstract][Full Text] [Related]
22. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
Zignol M; Peracchi M; Tridello G; Pillon M; Fregonese F; D'Elia R; Zanesco L; Cesaro S
Cancer; 2004 Aug; 101(3):635-41. PubMed ID: 15274078
[TBL] [Abstract][Full Text] [Related]
23. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely.
Omeñaca F; Garcia-Sicilia J; Boceta R; Sistiaga-Hernando A; García-Corbeira P
Pediatr Infect Dis J; 2007 Sep; 26(9):824-9. PubMed ID: 17721379
[TBL] [Abstract][Full Text] [Related]
24. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
25. Concurrent administration of rhesus rotavirus tetravalent (RRV-TV) vaccine with pentavalent diphtheria-pertussis-tetanus-Haemophilus influenzae beta-inactivated polio and hepatitis B vaccines.
Vesikari T; Joensuu J; Baer M; Käyhty H; Olander RM; Sormunen H; Miettinen A; Ward RL; Guillot T
Acta Paediatr; 1999 May; 88(5):513-20. PubMed ID: 10426173
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
Pichichero ME; Bernstein H; Blatter MM; Schuerman L; Cheuvart B; Holmes SJ;
J Pediatr; 2007 Jul; 151(1):43-9, 49.e1-2. PubMed ID: 17586189
[TBL] [Abstract][Full Text] [Related]
27. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
[TBL] [Abstract][Full Text] [Related]
28. Long-term antibody persistence against hepatitis B in adolescents 14-15-years of age vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy.
Schwarz TF; Behre U; Adelt T; Donner M; Suryakiran PV; Janssens W; Mesaros N; Panzer F
Hum Vaccin Immunother; 2019; 15(1):235-241. PubMed ID: 30118633
[TBL] [Abstract][Full Text] [Related]
29. Antibody responses of healthy infants to concurrent administration of a bivalent haemophilus influenzae type b-hepatitis B vaccine with diphtheria-tetanus-pertussis, polio and measles-mumps-rubella vaccines.
West DJ; Rabalais GP; Watson B; Keyserling HL; Matthews H; Hesley TM
BioDrugs; 2001; 15(6):413-8. PubMed ID: 11520252
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years.
Black S; Friedland LR; Schuind A; Howe B;
Vaccine; 2006 Aug; 24(35-36):6163-71. PubMed ID: 16759769
[TBL] [Abstract][Full Text] [Related]
31. Measles, mumps and rubella vs diphtheria-tetanus-acellular-pertussis-inactivated-polio-Haemophilus influenzae type b as the most recent vaccine and risk of early 'childhood asthma'.
Rieckmann A; Hærskjold A; Benn CS; Aaby P; Lange T; Sørup S
Int J Epidemiol; 2019 Dec; 48(6):2026-2038. PubMed ID: 31062020
[TBL] [Abstract][Full Text] [Related]
32. Infant vaccine co-administration: review of 18 years of experience with GSK's hexavalent vaccine co-administered with routine childhood vaccines.
Dolhain J; Janssens W; Dindore V; Mihalyi A
Expert Rev Vaccines; 2020 May; 19(5):419-443. PubMed ID: 32419537
[TBL] [Abstract][Full Text] [Related]
33. Lasting immune memory against hepatitis B in 12-13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy.
Behre U; Van Der Meeren O; Crasta P; Hanssens L; Mesaros N
Hum Vaccin Immunother; 2016 Nov; 12(11):2916-2920. PubMed ID: 27653771
[TBL] [Abstract][Full Text] [Related]
34. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E
Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579
[TBL] [Abstract][Full Text] [Related]
35. Recommended childhood immunization schedule--United States, 1997.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1997 Jan; 46(2):35-40. PubMed ID: 9011782
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age.
Diaz-Mitoma F; Halperin SA; Tapiero B; Hoffenbach A; Zappacosta PS; Radley D; Bradshaw S; Martin JC; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
Vaccine; 2011 Feb; 29(6):1324-31. PubMed ID: 21134456
[TBL] [Abstract][Full Text] [Related]
37. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants.
Zepp F; Knuf M; Heininger U; Jahn K; Collard A; Habermehl P; Schuerman L; Sänger R
Vaccine; 2004 Jun; 22(17-18):2226-33. PubMed ID: 15149781
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.
Olivier C; Belohradsky BH; Stojanov S; Bonnet E; Petersen G; Liese JG
Vaccine; 2008 Jun; 26(25):3142-52. PubMed ID: 18502545
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452
[TBL] [Abstract][Full Text] [Related]
40. Four is better than nine. a combined diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine for routine immunization in Malaysia.
Wong SL; Soosai P; Teoh YL; Han HH; Lefevre I; Bock HL
Southeast Asian J Trop Med Public Health; 2008 May; 39(3):474-83. PubMed ID: 18564687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
